These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35093013)

  • 21. Acupuncture for the prevention of episodic migraine.
    Linde K; Allais G; Brinkhaus B; Fei Y; Mehring M; Vertosick EA; Vickers A; White AR
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD001218. PubMed ID: 27351677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
    Melo-Carrillo A; Strassman AM; Schain AJ; Adams AM; Brin MF; Burstein R
    Cephalalgia; 2021 Jan; 41(1):17-32. PubMed ID: 33200944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 24. Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Strassman AM; Melo-Carrillo A; Houle TT; Adams A; Brin MF; Burstein R
    Cephalalgia; 2022 Aug; 42(9):933-943. PubMed ID: 35332801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
    Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
    Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
    Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
    Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.
    Gao B; Lu Q; Wan R; Wang Z; Yang Y; Chen Z; Wang Z
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):819-828. PubMed ID: 33136176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
    Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials.
    Gao B; Sun N; Yang Y; Sun Y; Chen M; Chen Z; Wang Z
    Front Neurol; 2020; 11():435. PubMed ID: 32508742
    [No Abstract]   [Full Text] [Related]  

  • 34. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials.
    Yan Z; Xue T; Chen S; Wu X; Yang X; Liu G; Gao S; Chen Z; Wang Z
    J Headache Pain; 2021 Mar; 22(1):10. PubMed ID: 33676408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for preventing migraine headaches in children.
    Victor S; Ryan SW
    Cochrane Database Syst Rev; 2003; (4):CD002761. PubMed ID: 14583952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atogepant.
    Am J Health Syst Pharm; 2022 Jan; 79(3):113-114. PubMed ID: 34964810
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.